The NICE guideline on endometriosis, first published in September 2017, was updated in April 2024. It addresses the diagnosis and management of endometriosis, particularly prioritizing fertility. It seeks to enhance awareness of endometriosis symptoms and offers clear guidance on referral, diagnosis, and the variety of available treatments.

Recent updates in endometriosis management (FOGSI-ICOG) include medical and surgical options. First-line treatments are NSAIDs, combined oral contraceptives (COCs), and progestogens (Dienogest, LNG-IUD). GnRH agonists/antagonists are second-line with add-back therapy. Aromatase inhibitors are third-line for resistant cases. Surgery is for severe or refractory cases, aiming to remove lesions while preserving function.

Higher blood eosinophil (EOS) levels were associated with improved survival in critically ill patients with heart failure with reduced ejection fraction (HFrEF) but not in those with preserved ejection fraction (HFpEF). A study of 2,677 HF patients found that those in the highest EOS quartiles had 63% lower in-hospital mortality, & improved 90-day survival. These findings suggest EOS to be a potential prognostic mark...

Heated tobacco products (HTPs) use in the first trimester significantly increased the risk of placental abruption (PA). A large cohort study found an 11.3-fold increased risk of PA among HTP users compared to non-users, with an absolute risk difference of 0.07. The strong association underscores the urgent need for awareness and smoking cessation interventions during pregnancy to prevent complications.

A study in Central India found ethambutol-induced optic neuropathy (EON) in 0.28% of TB patients. Prolonged treatment duration was associated with thickening of the left temporal and peripapillary retinal nerve fibre layer, indicating a higher risk of visual impairment. Interestingly, adverse effects were observed even at lower doses (12.3 mg/kg), suggesting that no dose is completely risk-free.

A study analyzing patients with head & neck squamous cell carcinoma (HNSCC) validated smoking duration (aHR: 1.11) & log cig-years (aHR: 1.11) as the best predictors of overall survival (OS). Both had significant linear correlation with OS, outperforming pack-years. Their predictive strength remained consistent across subgroups & tumor sites, suggesting their superiority in evaluating smoking's impact on survival.